NVMI: Held by 1 Biotech Hedge Fund (2026)

NVMI: Held by 1 Biotech Hedge Fund (2026) | BiotechEdge

Catalysts

Phase 3Q4 2007Methylene BlueBipolar DisorderNCT00214877

Primary: Young Mania Rating ScaleEnrollment:Target 40Sites: 2RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q3 2008Alcohol Consumption, Fetal Alcohol Syndrome Disorders, StudentsNCT00219336

Primary: AEP reduced risk through reduced drinking and effective contraception, or both (6 months post intervention)Enrollment:354/354Sites: 1RANDOMIZED, PREVENTION

Phase 2NegativeQ1 2009dimethyl sulfoxideInterstitial Cystitis, Bladder DiseasesNCT00317070

Primary: reduction of frequency of micturition (16 weeks)Enrollment:10/10Sites: 1RANDOMIZED, SINGLE, TREATMENT

Phase 3Q1 2011HIVNCT00780260

Primary: Substance abuse treatment linkage at 3 months (3 months)Enrollment:562/562Sites: 1RANDOMIZED, HEALTH_SERVICES_RESEARCH

Phase 2Q4 2011HIV Infection, Substance AbuseNCT01327898

Primary: unprotected anal intercourse events outside of primary relationships (3 months)Enrollment:515/515Sites: 2RANDOMIZED, PREVENTION

Phase 3NegativeQ1 2013paroxetineMajor Depressive DisorderNCT00400088

Primary: Response will be defined as 50% reduction in MADRS score. (weekly)Enrollment:2/2Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2013Rectal CancerNCT00297791

Primary: locoregional recurrence rate (3 years post operatively)Enrollment:1,044/1,044Sites: 35NON_RANDOMIZED, TREATMENT

Phase 2Q1 2014Unsafe Sex, Risk ReductionNCT01376895

Primary: unprotected sex (last 3 month)Enrollment:211/211Sites: 1RANDOMIZED, SINGLE, PREVENTION

Phase 3Q2 2014Lung DiseasesNCT01235481

Primary: 6MWD (6 months)Enrollment:90/90Sites: 2RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2014NiaspanPsychosisNCT01720095

Primary: standardized and experimental measures of attention, memory, and executive function. Measurement tools=MATRICS; DalCAB (change in cognitive function from baseline to 3, 6, and 12 months)Enrollment:22/22Sites: 1RANDOMIZED, TREATMENT

Phase 2Q2 2016Botulinum Toxin Type AScarNCT01177358

Primary: Vancouver Scar Scale (6 months)Enrollment:40/40Sites: 1RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3NegativeQ1 2018PlaceboFatigueNCT01912261

Phase 2Q2 2024Psilocybin, 1.5 mgFragile X Syndrome, Behavior, Cognitive DysfunctionNCT05832255

Phase 2Q3 2025Triple Negative Breast Cancer (TNBC)NCT06880029

Phase 2Q1 2026Floradapt Intensive GIME/CFS, IBS - Irritable Bowel SyndromeNCT06211062

Phase 2Q2 2026PlaceboGulf War IllnessNCT04927338

Phase 2Q2 2027NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)Knee OsteoarthritisNCT06606561

Phase 2Q2 2027growth factors to help in regenerationIntrabony Periodontal DefectNCT05442034

Phase 2Q2 2028Human Interleukin-2 (IL-2) (Proleukin)Triple Negative Breast CancerNCT05821686

Phase 2Q2 2028Antidepressant medicationDepressionNCT05002309

NOVA LTD.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research